-
Uncategorized1 week ago
#AAD26: Biogen declares Phase 2 lupus success for anti-BDCA2 antibody
#AAD26: Biogen declares Phase 2 lupus success for anti-BDCA2 antibody
-
Uncategorized1 week ago
#AAD26: Tanabe’s Phase 3 win for drug targeting rare diseases that cause pain upon light exposure
Tanabe Pharma unveiled positive data from a Phase 3 trial of its oral drug for a pair of rare diseases, its first major clinical milestone after...
-
Uncategorized2 weeks agoOtsuka picks up PTSD drug with $700M Transcend buy
The buyout, which includes another $525 million in floated payouts, hands Otsuka a medicine it sees as a possibly “paradigm-shifting therapy” in psychiatry.
-
Uncategorized2 weeks ago
Webinar: Aligning With the FDA on a Regulatory Pathway To Avoid Decision Day Surprises
Watch this critical discussion on how regulators and biotech companies can bridge the expectation gap during the regulatory review process to ensure novel therapies reach patients...
-
Uncategorized2 weeks agoThis week in Drug Discovery (23 – 27 March)
News round-up for 23 – 27 March February by Bruno Quinney, Content Team at DDW. This week, obesity could be treated in other ways than through drugs suppressing appetite. Elsewhere, prostate cancer...
-
Uncategorized2 weeks ago
After Speaking out of Turn, Malone Steps Down From Vaccine Committee
Former ACIP vice chair Robert Malone claimed that Andrew Nixon, spokesperson for the Department of Health and Human Services, “trashed” him with the media, adding that...
-
Uncategorized2 weeks agoBeam reports positive data for genetic disease treatment
Biotechnology company Beam Therapeutics has reported encouraging data for its treatment for the genetic disease Alpha-1 Antitrypsin Deficiency (AATD). Beam announced BEAM-302, a liver-targeting lipid-nanoparticle (LNP) formulation...
-
Uncategorized2 weeks ago
Rocket’s Gene Therapy Wins FDA Greenlight, Clearing Way for Future Products
While the accelerated approval unlocks only a small market opportunity for Rocket Pharmaceuticals, it will give the biotech a chance to prepare for future product launches,...
-
Uncategorized2 weeks ago
Novartis Keeps Deals Coming With $2B Excellergy Takeover
The Excellergy acquisition will complement Novartis’ existing allergy profile, anchored by the IgE blocker Xolair that in February 2024 was approved to treat food allergies in...
-
Uncategorized2 weeks ago
Eisai, Alzheon Drill Down on Promising Results in High-Risk Alzheimer’s Subset
At the AD/PD annual meeting, Eisai presented real-world data suggesting Leqembi’s long-term safety and efficacy in people homozygous for APOE4, who were identified in trials as...
Sanofi Bispecific Scores in Asthma, Rhinosinusitis, but Eczema Bet Doesn’t Pay Off
